



This presentation and the accompanying slides (the "Presentation"), which have been prepared by Quick Heal Technologies Ltd. (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward-looking statements concerning the Company's future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward-looking statements become materially incorrect in future or update any forward-looking statements made from time to time by or on behalf of the Company.

Quick Heal acknowledges the ownership rights of third parties to the intellectual property rights mentioned in this document. Other logos/trademarks mentioned in the presentation belongs to respective owners and used only for reference purpose.







# Agenda

01

02

03

04



Q2FY22 Earnings Highlights



Company Overview



<u>គ្</u>វី ម៉ូ ក្ន

The Quick Heal Advantage

05

Q2FY22 & H1FY22 Earnings



# Q2FY22 Earnings Highlight







**Q2FY22** Revenue at

₹1,038 mln

Up 23% from Q2FY21

#### **CASH PAT**

Q2FY22 Cash PAT at

₹388 mln

Up 15% from Q2FY21

#### **EBITDA**



**Q2FY22** EBITDA at

₹463 mln

Up 18% from Q2FY21

**Retail** at

₹906 mln

Up 18% from Q2FY21

#### **PAT**

Q2FY22 PAT at

₹346 mln

Up 20% from Q2FY21

**Enterprise** at

₹**209** mln

Up 16% from Q2FY21

## **Q2FY22 Revenue split**

**Retail 81.3%** 



## New enterprise customers with more than 500 users added in FY21-22

Quarter	>=500 To <=999	>=1000 To <=4999	>=5000	Grand Total
Q1 FY 2022	08	02	0	10
Q2 FY 2022	18	05	1	24



# Company at a glance





#### **Vision**

To be the trusted global leader in securing the digital world

#### **Mission**


Secure our customers by providing innovative, most preferred and valued security solutions, services and knowledge

Protect information and interactions on all types of networks, devices & things globally

Build a healthy business and organization

# Our journey





# Over 25 years of simplifying security

# Scripting a new success story In the cybersecurity industry

# **Quick Heal**





₹ 906 mln Q2FY22 Revenue\*







₹209 mln Q2FY22 Revenue\*
















\*Based on net revenues before adjusting for sales incentives

- India's first listed cybersecurity products company
- A "Make in India" product configured to secure countries, cities and companies
- Quick Heal undisputed leader in the retail segment
- Seqrite making inroads in the SMB & enterprise segment
- Quick Heal Security Labs a team of highly efficient security researchers, analysts and engineers leverages a combination of AI, cloud and patented technologies to deliver timely and advanced protection
- Solutions to secure across platforms

# **Shareholding Information**



### **Shareholding structure - 30th September 2021**



# Shareholder Information (as on 30th September 2021)

NSE Ticker	QUICKHEAL
BSE Ticker	539678
Market Cap (INR mln)	13,682
% Free-float	27.01%
Free-float market cap (INR mln)	3,696
Total Debt (INR mln)	-
Cash & Cash Equivalents (INR mln)	3,166
Shares Outstanding	5.79,02,251
3M ADTV (Shares)*	4,32,204
3M ADTV (INR mln)*	116.7
Industry	IT Software Products

<sup>\*</sup>Source: NSE





# INDUSTRY OVERVIEW


# 2021 Cyber threat landscape shows that...




#### **Detection Highlights - Q2 2021\***



\*Top seven malware categories features in the chart



#### States most affected




Source: Segrite Threat Report Q2 2021

Source: Quick Heal Threat Report 2021

# ...cyber attacks continue to grow in scale and sophistication







Source: IBM

Cyber-attacks that grabbed headlines



Indian hackers behind attack on FBR website - Business Recorder (September 10, 2021)

TN government systems under cyber attack: Probe on - The New Indian Express (September 19, 2021)

Chinese Hackers Targeted Aadhaar Database, Times Group: Report - The NDTV (September 22, 2021)

Indian SMBs lost upto ₹7 crore in cyber attacks in last 12 months - The Hindu (September 21, 2021)

83% organizations in India saw rise in phishing attacks during pandemic - The Mint (September 20, 2021)


71 per cent organisations attribute recent cyberattacks to vulnerabilities in technology - Business Line (September 25, 2021)


Source: Reputed News Outlets

...and rapid digitization has enhanced need for greater Quick Heal cybersecurity investments











Internet users

Internet usage (FY16 - FY21)



Mobile data usage (FY16-FY21)



People enrolled in the world's largest unique digital identity program



Internet penetration in India in 2021



Users engaged in social media



**Application** downloads in 2020



Rs.**6.98** 

Average cost to subscriber per GB wireless data

Source: The Ministry of Electronics and Information Technology, TRAI, Government of India, Statista, Google report - Insights for Brands, KPMG Report - Fintech In India, India Data Diviner - Macquarie, Nokia MBIT, Goldman Sachs Investment Research - Portfolio Strategy Research (Sept 19, 2021)



# Cyber threat predictions for 2021 and beyond





01

Threat Actors to switch from Ransomware to RansomHack: Double - Trouble for Enterprises 02

Targeted
Ransomware attacks
on Healthcare and
Pharma Sector
to Surge

03

Techniques similar to Operation SideCopy 04

CobaltStrike:
Powerhouse of
Ethical Hackers
in the Hands of
Cyber Criminals

05

Increase in threats on Remote Work Infrastructure 06

Next wave of Cryptominers 07

Coronavirus themed threats to divert from precaution-based to prevention-based 08

New additions in exploits leveraging weak crypto implementations

09

Deep-fakes to cyber-frauds

10

Automation in performing phishing attacks

п

Attacks on Red Team tools

12


Increase in attacks related to mobile banking

Source: Segrite Threat Predictions 2021



# Quick Heal is well positioned to leverage its strengths to capture the future opportunities






# Strong threat detection and prevention capabilities...









#### Powers **SIGNATURE-LESS** and **SIGNATURE-BASED** detections

Our best and the most innovative malware hunting engine brings together the best of the best!













# Research & Development leading to Innovations

25+ years of experience coupled with vast distribution network across India has helped us understand security market and issues faced by millions of users in depth which has led to consistent introduction of innovative products and solutions for our customers



connected devices

are secure

# Product Portfolio - Home, SOHO & Mobile





## Robust sales & distribution network in India



#### **Sales Execution**

Robust pan India coverage

# Complimentary support from Quick Heal

Zonal and regional sales team to engage and support channel

## **Metro Sales Coverage**

Strong presence across the top metros in India.
Coverage through T1
distributors and T2 resellers

# Landscape across Class B &C towns

Growing presence of T1 distributors across B&C towns. Strong network of T2 resellers - across Class B and Class


#### **Presence in Class A towns**

Strong distribution across Class A towns backed by T2 resellers

For details of Sales & support office across India refer annexure (Slide no. 33)

## **QUICK HEAL Global Presence**







# Committed to deliver exceptional





# customer experience

- Multi-lingual end user support in English, Hindi and several other major regional Indian languages
  - 2 Availability of data sheets, product videos and manuals on website for providing information on technical specifications, installation guide, upgrade mechanisms
    - Release of various articles, technical papers, quarterly threat reports and conducting webinars in the area of security software



# **Experienced Board of Directors**





Dr. Kailash Katkar MD & CEO

Drives the strategic direction for the company while nurturing a strong leadership team to drive its execution



Dr. Sanjay Katkar Joint MD & CTO

Spearheads the creation and subsequent development of the core product technology



Mr. Shailesh Lakhani Non-Executive Director

Serves as the MD at Sequoia Capital India. Previously, he worked at Redknee's India subsidiary as the Managing Director



Mr. Amitabha Mukhopadhyay Independent Director

Over three decades of experience in corporate finance, legal and litigation, strategy and M&A. Served as the Group CFO of Thermax



Air Marshal (Retd) Bhushan Nilkanth Gokhale Independent Director

Served on the board of defense PSUs and adviser to government institutions. Appointed as Independent Security Advisor in Ministry of Home Affairs.



Mr. Mehul Savla Independent Director

Serves as Director for RippleWave Equity Advisors LLP. Previously worked at JP Morgan, ICICI Securities and SEBI



Ms. Apurva Joshi Independent Director

Certified bank forensic accounting professional and anti-money laundering expert



Mr. Richard Stiennon
Independent Director

Serves as Chief Research Analyst at IT-Harvest, and sits on the advisory boards of several start-ups. Advised boards of global companies like Symantec, McAfee, Cisco, Microsoft and Trend Micro.

# ...along with strong Management...





Dr. Kailash Katkar *MD & CEO* 

#### **Co-founder of the Company**

Has been the driving force in growing Quick Heal Technologies since it's inception.

A proven leader with a profound proficiency in developing strong client relationships, passion for building outstanding teams and a disciplined focus on operations & execution of strategy.



Dr. Sanjay Katkar

Joint MD & CTO

#### **Co-founder of the Company**

Leads the global technology strategy & is responsible for the core research & development of the products.

Has served as the Director of Association of Anti-Virus Researchers, Asia and is a distinguished speaker at various industry forums.

Holds Master's degree in Computer Science from the University of Pune.

# ...and seasoned Leadership team





Mr. Nitin Kulkarni *CFO* 

25+ years of experience in managing different aspects of finance in IT and Manufacturing Industry.

Previously held leadership positions at Tech Mahindra, KPIT, Atlas Copco India and Persistent Systems.

A member of the Institute of Chartered Accountants of India.



Ms. Reetu Raina

Responsible for driving HR and steering the company's people operations, culture and recruitment initiatives.

Ms. Raina holds extensive industry experience and has worked across sectors such as Telecom, BFSI, and IT.

She has held leadership roles with domain-leading brands such as TATA, HDFC Bank, and Amdocs. She was the Head of HR at Sterlite Technologies.



Mr. Sanjay Agrawal

Responsible for driving the overall product vision and strategy in line with market expectations.

Sanjay is an entrepreneurial engineering and product leader with two decades of experience and proven success in building cybersecurity products for the global markets.

A computer engineering graduate from University of Illinois, Sanjay holds a Ph.D. and M.S. from Stanford University in Electrical Engineering and Computer Science (EECS).

# ...and seasoned Leadership team



Mr. Bibhuti Kar Head, R&D

Responsible for driving company's development efforts leading a team of talented engineering professionals and security researchers.

Bibhuti brings with him over two and a half decades of rich experience in the global high-tech industry.

An alumnus of IIT Kharagpur with a master's in ECE, he has worked on missile communication systems with DRDO.



Mr. Kuldeep Raina Head, Global Enterprise Sales

Responsible for leading the enterprise and government sales strategy and managing the vertical on a global level.

Passionate technocrat with a rich flare for sales and ability to drive targets in dynamic business environment.

Over two decades of diverse sales experience including leadership roles in cybersecurity companies.





Mr. Deepak Mishra Head, Retail Sales

Responsible for enhancing market share and driving channel strategy for the retail brand.

Has extensive exposure in sales and distribution, channel management, and building a robust distribution to drive productivity and profitability.

Over two decades of experience in FMCG, Beverages, Telecom and IT Industries.





# Strong brand recognition...



Certified as 'Approved Corporate Endpoint Protection' for Windows by 'AV-Test' 2018



Best cybersecurity brand award at National Summit on Digital Innovation & Cybersecurity Summit 2018



Recognized by NASSCOM's DSCI as 'Cybersecurity Product Pioneer in India' 2019



**'Best Performance 2018'** award for its Endpoint Security Solution from AV-Test Institute in Germany 2019



**Quick Heal Technologies** 

Granted Patent for Anti-Ransomware Technology 2019 U.S. Patent No. US20160378988A1



**Quick Heal Technologies** 

Granted Patent for its **Signatureless Behavior-based Detection Technology** 2019
U.S Patent No.
US20170124327A1



Seqrite Endpoint Security

Certified as **'Top Product'** for
business users
by **'AV-Test'** in 2020



Quick Heal Total Security

Certified as **'Top Product'** for
consumers
by **'AV-Test'** in 2020



Seqrite Endpoint Security

Certified and approved **by ICSA Labs** in 2020



**Quick Heal** 

**Best AV of 2020** at the 13th NCN Innovative Product Award 2021





Seqrite Endpoint Security

Certified as 'Top Product' for enterprises by AV-Test in 2021



# ...backed by Certifications, Patents and...

#### International & ISO Certifications















#### **Patented Technologies**

USPTO 10,387,649

Signatureless Behaviour-based Detection Technology

USPTO 10,311,234

Anti-Ransomware technology

USPTO 8,973,136

System and method for protecting computer systems from malware attacks

**USPTO 8,914,908** 

A completely automated computer implemented system and method for piracy control based on update requests

USPTO 8,347,389

System for protecting devices against virus attacks

USPTO 7,945,955

Virus detection in mobile devices having insufficient resources to execute virus detection software







# ...CSR initiatives through Quick Heal Foundation





## **Education**

Cyber Shiksha for Cyber Suraksha

2 states

2 schools

1 college

eRYLA

10000+

Participants from Indonesia, USA, Pakistan, Australia, UAE, Sri Lanka, South Africa, Jamaica

## Healthcare

Arogya Yan

6 States, 8 Arogya Yan, 350+ villages

Lives touched

2 Lakh+

#### Covid Care Centre

2 covid care centres 1 in association with CYDA First children Covid Care Centre in Pune Consumable donations like masks, surgical gloves, oxyzen concentrator etc.

Lives touched

60000+

Vaccination drive

in Satara district

2000+

doses administered

Flood relief in Kolhapur

Distribution of blanket, satranji, food grains, etc.

Lives touched

42000+

# Quick Heal Academy to drive the next generation of cyber security experts





#### **Popular Courses**

- ✓ Cyber Security and Forensics
- ✓ Cyber Threat Intelligence
- ✓ Malware Analysis & Reverse Engineering
- √ Security Operations Centre (SOC)
- ✓ Electronic Crime Scene Investigation

#### Offerings







& SEMINARS



CORPORATE NEED-BASED TRAINING TRAINING

CONNECTING CYBER ECO-SYSTEM

#### **Academy Partners**

## Savitribai Phule Pune University

Designed 'M-Tech in Information Security' Program for Savitribai Phule Pune University

#### **Quantum University**

W

Quantum

司

**CHITKARA** 

MoU with Quantum University for a joint B.Tech (Hons.) with specialization in Cyber Security

#### **Gujarat Forensic Sciences University**

MoU with Gujarat Forensic Sciences University during Vibrant Gujarat 2017

#### Maharashtra Cosmopolitan Education Society

The society runs 30 institutes from its ultra modern campaigns located in Maharashtra

#### Chitkara University

MoU with Chitkara University Introduced an additional stream in Cyber Security for the four-year Undergraduate program

#### Deen Dayal Upadhyaya College


MoU with Deen Dayal Upadhyaya College, a constituent college of the University of Delhi






# Q2FY22 - Consolidated Performance Highlights









<sup>\*</sup>As per Ind AS # Cash PAT = PAT + Depreciation

# H1FY22 - Consolidated Performance Highlights







<sup>\*</sup>As per Ind AS # Cash PAT = PAT + Depreciation

## Q2FY22 Segment performance







#### Retail


**Enterprise & Government** 


Revenue break-up





Licenses Sold Analysis





## HIFY22 Segment performance






#### Retail


### **Enterprise & Government**


Revenue break-up





Licenses Sold Analysis





# Q2FY22 - Profitability statement





DARTICIU ARS (# mln)	Standal			Co	onsolidated	
PARTICULARS (₹ mln)	Q2FY21	Q2FY22	% change	Q2FY21	Q2FY22	% change
Total Revenue	828.60	1,037.92	25.26%	844.13	1037.85	22.95%
Direct Cost	33.48	44.29		36.11	44.28	
Gross Profit	795.12	993.63	24.97%	808.02	993.57	22.96%
Gross Margin	95.96%	95.73%	-23bps	95.72%	95.73%	1bps
Operating Cost						
Research and Development (R&D)	168.89	201.02		168.89	201.02	
Sales and Marketing (S&M)	138.28	201.06		142.24	204.14	
General Administration (G&A)	100.62	128.58		106.03	125.33	
Total Expenditure	407.79	530.66	-30.13%	417.16	530.49	-27.17%
EBITDA	387.33	462.97	19.53%	390.86	463.08	18.48%
EBITDA Margin	46.75%	44.61%	-214bps	46.30%	44.62%	-168bps
Depreciation	48.74	41.58		48.79	41.62	
EBIT	338.59	421.39	24.45%	342.07	421.46	23.21%
EBIT Margin	40.86%	40.60%	-26bps	40.52%	40.61%	9bps
Other Income	57.19	36.49		58.25	36.51	
Profit Before Tax (PBT after exceptional item)	395.78	457.88	15.69%	400.32	457.97	14.40%
Tax	111.77	111.40		111.97	111.69	
Profit After Tax (PAT)	284.01	346.48	22.00%	288.35	346.28	20.09%
PAT Margin	34.28%	33.38%	-89bps	34.16%	33.37%	-79bps

# H1FY22 - Profitability statement





DARTICIII ARS (# mln)	Standalone		Consolidated			
PARTICULARS (₹ mln)	H1FY21	H1FY22	% change	H1FY21	H1FY22	% change
Total Revenue	1,563.00	1,581.75	1.20%	1,578.75	1,585.69	0.44%
Direct Cost	62.49	60.75		65.14	57.91	
Gross Profit	1,500.51	1,521.00	1.37%	1,513.61	1,527.78	0.94%
Gross Margin	96.00%	96.16%	16bps	95.87%	96.35%	47bps
Operating Cost						
Research and Development (R&D)	318.50	394.78		318.50	394.78	
Sales and Marketing (S&M)	261.68	359.67		269.71	365.43	
General Administration (G&A)	204.75	259.31		213.18	252.48	
Total Expenditure	784.93	1,013.76	-29.15%	801.39	1,012.69	-26.37%
EBITDA	715.58	507.24	-29.11%	712.22	515.09	-27.68%
EBITDA Margin	45.78%	32.07%	-1371bps	45.11%	32.48%	-1263bps
Depreciation	95.24	82.54		95.30	82.60	
EBIT	620.34	424.70	-31.54%	616.92	432.49	-29.90%
EBIT Margin	39.69%	26.85%	-1284bps	39.08%	27.27%	-1180bps
Other Income	119.82	98.84		121.40	99.02	
Profit Before Tax (PBT after exceptional items)	740.16	523.54	-29.27%	738.32	531.51	-28.01%
Exceptional items	-	21.64		-	-	
Profit Before Tax	740.16	501.90	-32.19%	738.32	531.51	-28.01%
Tax	199.82	122.81		200.39	123.40	
Profit After Tax (PAT)	540.34	379.09	-29.84%	537.93	408.11	-24.13%
PAT Margin	34.57%	23.97%	-1060bps	34.07%	25.74%	-834bps

# Q2FY22 - Ratio analysis



La O/	Stand	Standalone		idated
In %	Q2FY21	Q2FY22	Q2FY21	Q2FY22
Expenses				
Direct Cost / Revenue	4.04%	4.27%	4.28%	4.27%
R&D / Revenue	20.38%	19.37%	20.01%	19.37%
S&M / Revenue	16.69%	19.37%	16.85%	19.67%
G&A / Revenue	12.14%	12.39%	12.56%	12.08%
Total Cost / Revenue	49.21%	51.13%	49.42%	51.11%
Margin				
Gross Margin	95.96%	95.73%	95.72%	95.73%
EBITDA	46.75%	44.61%	46.30%	44.62%
EBIT	40.86%	40.60%	40.52%	40.61%
PBT	47.76%	44.12%	47.42%	44.13%
PAT	34.28%	33.38%	34.16%	33.37%

# H1FY22 - Ratio analysis



	Stand	alone	Consolidated	
In %	H1FY21	H1FY22	H1FY21	H1FY22
Expenses				
Direct Cost / Revenue	4.00%	3.84%	4.13%	3.65%
R&D / Revenue	20.38%	24.96%	20.17%	24.90%
S&M / Revenue	16.74%	22.74%	17.08%	23.05%
G&A / Revenue	13.10%	16.39%	13.50%	15.92%
Total Cost / Revenue	50.22%	64.09%	50.76%	63.86%
Margin				
Gross Margin	96.00%	96.16%	95.87%	96.35%
EBITDA	45.78%	32.07%	45.11%	32.48%
EBIT	39.69%	26.85%	39.08%	27.27%
PBT	47.36%	33.10%	46.77%	33.52%
PAT	34.57%	23.97%	34.07%	25.74%

## **Consolidated Balance Sheet**





<b>EQUITY AND LIABILITIES</b> (₹ mln)	Sep 30, 2020	Sep 30, 2021
Share Holder's Funds:		
Equity Share Capital	642.03	579.01
Share application money pending allotment	-	0.03
Reserves and Surplus	6,341.20	5,205.94
Total Shareholder Funds	6,983.23	5,784.98
Non-Current Liabilities		
Net employee defined benefit liabilities	6.86	2.03
Other Non Current Liabilities	0.30	-
Deferred tax liability (net)	-	6.14
Total Non-Current Liabilities	7.16	8.17
Current Liabilities:		
Trade and Other Payables	501.73	500.02
Other Financial Liabilities	18.15	12.22
Other Current Liabilities	142.54	172.98
Net employee defined benefit liabilities	11.42	13.75
Current tax liabilities (Net)	136.97	1.62
Total Current Liabilities	810.81	700.59
Total Equity & Liabilities	7,801.20	6,493.74

ASSETS (₹ mln)	Sep 30, 2020	Sep 30, 2021
Non-Current Assets:		
Property, plant and equipment	1,427.40	1,361.70
Capital work-in-progress	34.00	21.10
Intangible assets	70.86	43.63
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	172.78	247.48
Loan and Security Deposits	3.82	3.65
Bank Balances	4.03	-
Deferred tax assets (net)	31.16	-
Other non current assets	211.23	129.46
Total Non-Current Assets	1,955.28	1,807.02
Current assets:		
Inventories	46.69	36.83
Investment in Mutual Fund	3,658.79	2,542.88
Trade and other receivables	1,327.97	1,469.35
Bank Balances & Cash and Cash Equivalents	128.09	158.12
Investment in Fixed Deposit	561.50	406.80
Loan and security deposits	8.03	3.93
Interest accrued on FDR & Tax-Free Bonds	12.77	5.46
Other Current assets	102.08	57.81
Assets classified as held for sale	-	5.54
<b>Total Current Assets</b>	5,845.92	4,686.72
Total Assets	7,801.20	6,493.74

NOTE: Certain figures have been re-grouped wherever necessary

## Standalone Balance Sheet





<b>EQUITY AND LIABILITIES</b> (₹ mln)	Sep 30, 2020	Sep 30, 2021
Share Holder's Funds:		
Equity Share Capital	642.03	579.01
Share application money pending allotment	-	0.03
Reserves and Surplus	6,387.57	5,220.84
Total Shareholder Funds	7,029.60	5,799.88
Non-Current Liabilities		
Net employee defined benefit liabilities	6.86	2.03
Other Non Current Liabilities	0.30	-
Deferred tax liability (net)	-	6.14
Total Non-Current Liabilities	7.16	8.17
Current Liabilities:		
Trade and Other Payables	500.29	503.55
Other Financial Liabilities	18.15	12.22
Other Current Liabilities	140.07	171.94
Net employee defined benefit liabilities	11.42	13.75
Current tax liabilities (Net)	136.37	1.21
Total Current Liabilities	806.30	702.67
Total Equity & Liabilities	7,843.06	6,510.72

		<u>'</u>
ASSETS (₹ mln)	Sep 30, 2020	Sep 30, 2021
Non-Current Assets:		
Property, plant and equipment	1,427.18	1,361.33
Capital work-in-progress	34.00	21.10
Intangible assets	70.68	43.49
Non-current financial assets		
Investments in MF ,Tax-Free Bonds & others	287.79	348.12
Loan and Security Deposits	3.82	3.65
Bank Balances	4.03	-
Deferred tax assets (net)	31.16	-
Other non current assets	211.23	129.46
<b>Total Non-Current Assets</b>	2,069.89	1,907.15
Current assets:		
Inventories	46.47	36.80
Investment in Mutual Fund	3,658.79	2,542.88
Trade and other receivables	1,315.42	1,475.03
Bank Balances & Cash and Cash Equivalents	68.73	70.86
Investment in Fixed Deposit	561.50	406.80
Loan and security deposits	7.96	3.86
Interest accrued on FDR & Tax-Free Bonds	12.77	5.46
Other Current assets	101.53	56.34
Assets classified as held for sale	-	5.54
Total Current Assets	5,773.17	4,603.57
Total Assets	7,843.06	6,510.72

NOTE: Certain figures have been re-grouped wherever necessary


## Working capital analysis



## At the end of September, 2020\*

## At the end of March, 2021\*\*

## At the end of September, 2021\*



#### Note\*

Receivable Days = [(Debtors/ Sales) X (183 days)]

Inventory Days = [(Inventory/Sales) X (183 days)]

Payable Days = [(Creditor/Sales) X (183 days)]

#### Note\*\*

Receivable Days = [(Debtors/ Sales) X (365 days)]

Inventory Days = [(Inventory/Sales) X (365 days)]


Payable Days = [(Creditor/Sales) X (365 days)]


## Return ratio analysis



## **Return on Capital Employed\***







- > Company is continuously evaluating strategic inorganic opportunities to invest across the cybersecurity ecosystem
- > Till such time the company invests its surplus cash in mutual funds, tax free-bonds and fixed deposits

**RoCE** = EBIT / Avg. Capital Employed (Equity + Debt)

**Cash Adj. RoCE** = EBIT / Avg. Cash Adj. Capital Employed (Equity + Debt – Cash & Cash Equivalents)

**ROE** = PAT / Avg. Equity





# Thank You

#### **Chief Financial Officer**

Mr. Nitin Kulkarni
Nitin.Kulkarni@quickheal.co.in
+91-20-66813232

## **Company Secretary**

Mr. Srinivas Anasingaraju cs@quickheal.co.in +91-20-66813232

## CIN No:

L72200MH1995PLC091408

www.quickheal.co.in

## **Annexure**



## Products Sold in following countries

- Australia
- Banaladesh
- Benin
- Cambodia
- Canada
- Chile
- Colombia
- Congo
- Ecuador
- El Salvador
- France
- Gambia

- Germany
- Guinea
- Honduras
- Hong Kong
- Italy
- Japan
- Jordan
- Kenya
- Kuwait
- Macao
- Malaysia
- Mauritius

- Mexico
- Morocco
- Netherlands
- New Zealand
- Niaeria
- Saudi Arabia
- Singapore
- Solomon Islands
- South Africa
- South Korea
- Sri Lanka
- Panama

- Paraguay
- Peru
- Philippines
- Qatar
- Rwanda
- Thailand
- Turkey
- Uganda
- UAE
- USA
- Venezuela

## Sales & Support offices across India

- Chandiaarh
- New Delhi
- Jaipur
- Lucknow
- Patna
- Guwahati
- Ahmedabad
- Indore
- Surat
- Nashik
- Nagpur

- Mumbai
- Pune
- Aurangabad
- Kolhapur
- Raipur
- Kolkata
- Bhubaneshwar
- Hyderabad
- Bangalore
- Chennai
- Kochi





Independent Auditor's Review Report on Consolidated Unaudited Quarterly and year to date financial results of the Group, its Associate and Jointly controlled entities pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

## The Board of Directors Quick Heal Technologies Limited

- 1. We have reviewed the accompanying statement of consolidated unaudited financial results of Quick Heal Technologies Limited ('the Holding Company'), its subsidiaries, (the Holding Company and its subsidiaries together referred to as the 'Group') for the quarter ended September 31, 2021 and the year to-date results for the period from April 1, 2021 to September 30, 2021 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulations'). This statement is the responsibility of the Holding Company's Management and has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the based on our review.
- 2. This Statement has been prepared by the Holding Company's Management in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. This Statement includes the results of the following entities:

Sr. No	Name of the Company	Relationship with the Holding Company
1.	Quick Heal Technologies Japan K.K.	Wholly Owned Subsidiary



2.	Quick Heal Technologies America Inc.	Wholly Owned Subsidiary
3.	Quick Heal Technologies Africa Limited	Wholly Owned Subsidiary
4.	Segrite Technologies DMCC	Wholly Owned Subsidiary

- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement are prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. The consolidated unaudited financial results include the interim financial statements/ financial information/ financial results of 4 subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total assets of Rs. 95.96 million as at September 30, 2021 and total revenue of Rs. 5.27 million and Rs. 17.84 million, total net profit/(loss) after tax of Rs. 0.21 million and Rs. 0.22 million and total comprehensive income / loss of Rs. 0.21 million and Rs. 0.22 million for the quarter ended September 30, 2021 and for the period from April 1, 2021 to September 30, 2021, respectively, and cash flows (net) of Rs. 18.38 million for the period from April 1, 2021 to September 30, 2021, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

#### For MSKA & Associates

Chartered Accountants ICAI Firm Registration No.105047W



**Partner** 

Membership No.: 111700 UDIN: 21111700AAAAGJ3265

Place: Pune

Date: October 25, 2021



Pune 411014, INDIA Tel: +91 20 6763 3400



Independent Auditor's Review Report on unaudited quarterly and year to date standalone financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors

**Quick Heal Technologies Limited** 

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Quick Heal Technologies Limited ('the Company') for the quarter ended September 30, 2021 and the year to-date results for the period April 1, 2021 to September 30, 2021 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, amended ('the Regulation'). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the based on our review.
- 2. This Statement has been prepared by the Company's Management in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether standalone financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be



disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

#### For MSKA & Associates

Chartered Accountants ICAI Firm Registration No.105047W



Partner

Membership No.: 111700 UDIN: 21111700AAAAGK7071

Place:

Date: October 25, 2021